

**In the claims:**

1. (Currently Amended) A method of administering to a subject in need thereof an effective amount of a cisplatin ~~active agent~~, said method comprising:  
administering to said ~~host~~ subject ~~said effective amount of a~~ cisplatin ~~active agent~~ in conjunction with an amount of a ~~cisplatin toxicity reducing agent~~ compound selected from TK-211; TK-295; TK-516; TK-523; TK-363; TK-204; TK-5145 and TK-5175 effective to reduce toxicity of said cisplatin ~~active agent~~.
2. (Currently Amended) The method according to Claim 1, wherein said cisplatin ~~active agent~~ and ~~cisplatin toxicity reducing agent~~ said compound are administered at the same time.
3. (Currently Amended) The method according to Claim 2, wherein said cisplatin ~~active agent~~ and ~~cisplatin toxicity reducing agent~~ said compound are administered as separate formulations.
4. (Currently Amended) The method according to Claim 2, wherein said cisplatin ~~active agent~~ and ~~cisplatin toxicity reducing agent~~ said compound are administered in a single formulation.
5. (Currently Amended) The method according to Claim 1, wherein said cisplatin ~~active agent~~ and ~~cisplatin toxicity reducing agent~~ said compound are administered sequentially.
6. (Currently Amended) The method according to Claim 5, wherein said cisplatin ~~active agent~~ is administered prior to said ~~cisplatin toxicity reducing agent~~ compound.

7. (Currently Amended) The method according to Claim 5, wherein said cisplatin ~~active agent~~ is administered after said ~~cisplatin toxicity reducing agent~~ compound.

8. (Currently Amended) The method according to Claim 1, wherein the amount of said ~~cisplatin toxicity reducing agent~~ compound is not more than about the amount of said cisplatin ~~active agent~~.

9.-16. (CANCELLED)

17. (Currently Amended) A method of treating ~~a host suffering from a cellular proliferative disease condition~~ ovarian cancer in a patient, said method comprising:

administering to said ~~host~~ patient ~~said an effective~~ amount of ~~a cisplatin active agent~~ cisplatin effective to treat said cancer in conjunction with an amount of ~~a cisplatin toxicity reducing agent~~ TK-211 effective to reduce toxicity of said cisplatin ~~active agent so that said host is treated for said cellular proliferative disease condition~~.

18. (Currently Amended) The method according to Claim 17, wherein said cisplatin ~~active agent~~ and ~~cisplatin toxicity reducing agent~~ said TK-211 are administered at the same time.

19. (Currently Amended) The method according to Claim 18, wherein said cisplatin ~~active agent~~ and ~~cisplatin toxicity reducing agent~~ said TK-211 are administered as separate formulations.

20. (Currently Amended) The method according to Claim 18, wherein said cisplatin ~~active agent~~ and ~~cisplatin toxicity reducing agent~~ said TK-211 are administered in a single formulation.

21. (Currently Amended) The method according to Claim 17, wherein said cisplatin ~~active agent~~ and ~~cisplatin toxicity reducing agent~~ said TK-211 are administered sequentially.

22. (Currently Amended) The method according to Claim 21, wherein said cisplatin ~~active agent~~ is administered prior to said ~~cisplatin toxicity reducing agent~~ TK-211.

23. (Currently Amended) The method according to Claim 21, wherein said cisplatin ~~active agent~~ is administered after said ~~cisplatin toxicity reducing agent~~ TK-211.

24. (Currently Amended) The method according to Claim 17, wherein the amount of said ~~cisplatin toxicity reducing agent~~ TK-211 is not more than about the amount of said cisplatin ~~active agent~~.

Claims 25 -30. (CANCELLED)